In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Veru Inc (NASDAQ: VERU), with a price target of $5. The company’s shares closed yesterday at $1.81.
“We note that VERU-111 (bisindole) is a New Chemical Entity (NCE) within Veru’s pipeline. It is an α and β tubulin dual inhibitor that binds to the colchicine binding site; it inhibits tubulin polymerization; and it is not a substrate for multi-drug resistance (MDRs). Dosed orally, VERU-111 has demonstrated significant anti-tumor activity in animal models of metastatic, castration and novel androgen blocking agent (abiraterone or enzalutamide) resistant prostate cancer. VERU-111 (PO 5 and 20 mg/ kg) significantly reduced tumors by 31% (p=0.049) and 49% (p=0.010) compared to vehicle. In addition, VERU-111 had anti-tumor effects in preclinical models for triple-negative breast cancer (TNBC), ovarian cancer, and pancreatic cancer.”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.7% and a 45.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Veru Inc with a $8.33 average price target, implying a 360.2% upside from current levels. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $10 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3 and a one-year low of $0.90. Currently, Veru Inc has an average volume of 142.7K.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VERU in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Veru, Inc. is a urology and oncology biopharmaceutical company, which engages in the development, manufacture, and marketing of consumer health care products. It operates through the Commercial; and Research and Development segments.